Quanterix Corporation is engaged in fueling scientific discovery through ultra-sensitive biomarker detection. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 138.90M.
Overvalued
The company’s latest PE is -1.71, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 42.63M shares, decreasing 10.46% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 123.87K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.35.